Find Segesterone Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Nestoron, 7759-35-5, Elcometrine, Segesterone acetate, St-1435, Segesterone acetate [usan]
Molecular Formula
C23H30O4
Molecular Weight
370.5  g/mol
InChI Key
CKFBRGLGTWAVLG-GOMYTPFNSA-N
FDA UNII
9AMX4Q13CC

Segesterone Acetate
Segesterone acetate is a steroidal progestin or synthetic progesterone and a 19-norprogesterone derivative with no CH3 group radical in position 6. In animal studies, segesterone acetate was shown to be one of the most potent progestins. It mediates progestational activity 100 times higher than that of [progesterone]. It is commonly sold under the brand names Nestorone and Elcometrine and serves as an active component in hormonal contraceptives. It is also used as a treatment for endometriosis in South American countries. Segesterone acetate binds selectively to progesterone receptors and not androgen receptors. Due to its rapid hepatic metabolism, segesterone acetate must be administered parenterally. Segesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel. On August 10, 2018, Annovera containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S. Food and Drug Administration (FDA) as the first and only contraceptive that provides an entire year of protection against unintended pregnancy while entirely under a woman's control. According to the Center for Disease Control, more than 43 million women in the U.S. are at risk of unintended pregnancy, which may be associated with an elevated risk for improper prenatal care, premature and low-birth-weight infants, and physical and mental health risks. The introduction of this new contraceptive method offers an expansion of birth control options for women while maintaining high efficacy and acceptability similar to existing shorter-acting combined hormonal methods. In clinical trials, Annovera achieved a 97.3% success in pregnancy prevention. Annovera is administered as a vaginal ring that is in place for 21 days and removed for 7 days each cycle. As with other hormonal contraceptives, Annovera carries the risk for serious cardiovascular events.
1 2D Structure

Segesterone Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(8R,9S,10R,13S,14S,17R)-17-acetyl-13-methyl-16-methylidene-3-oxo-2,6,7,8,9,10,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
2.1.2 InChI
InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1
2.1.3 InChI Key
CKFBRGLGTWAVLG-GOMYTPFNSA-N
2.1.4 Canonical SMILES
CC(=O)C1(C(=C)CC2C1(CCC3C2CCC4=CC(=O)CCC34)C)OC(=O)C
2.1.5 Isomeric SMILES
CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C
2.2 Other Identifiers
2.2.1 UNII
9AMX4Q13CC
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 16-methylene-17alpha-acetoxy-19-nor-4-pregnen-3,20-dione

2. St 1435

3. St-1435

2.3.2 Depositor-Supplied Synonyms

1. Nestoron

2. 7759-35-5

3. Elcometrine

4. Segesterone Acetate

5. St-1435

6. Segesterone Acetate [usan]

7. 17-hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione Acetate

8. 9amx4q13cc

9. 16-methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dione

10. 19-norpregn-4-ene-3,20-dione, 17-(acetyloxy)-16-methylene-

11. Segesterone Acetate (usan)

12. St 1435

13. (8r,9s,10r,13s,14s,17r)-17-acetyl-13-methyl-16-methylene-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl Acetate

14. Unii-9amx4q13cc

15. Segesterone-acetate

16. Nestorone (tn)

17. [(8r,9s,10r,13s,14s,17r)-17-acetyl-13-methyl-16-methylidene-3-oxo-2,6,7,8,9,10,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-17-yl] Acetate

18. 16-methylene-17alpha-acetoxy-19-nor-4-pregnen-3,20-dione

19. Elcometrine [mi]

20. Schembl1261001

21. Chembl3707377

22. Elcometrine;nestorone;st-1435

23. Nestorone, >=97% (hplc)

24. Dtxsid70998804

25. Chebi:135563

26. 16-methylene-17-hydroxy-19-norpregn-4-ene-3,20-dione Acetate

27. Bcp12737

28. Zinc5167230

29. 19-norpregn-4-ene-3,20-dione, 17-hydroxy-16-methylene-, Acetate

30. Segesterone Acetate [who-dd]

31. Akos025402243

32. Ac-6844

33. Cs-0411

34. Db14583

35. Ncgc00487114-02

36. Segesterone Acetate [orange Book]

37. Hy-13071

38. Annovera Component Segesterone Acetate

39. D10986

40. E89278

41. Segesterone Acetate Component Of Annovera

42. 759n355

43. A914499

44. Elcometrine;nestorone;st-1435;st 1435;st1435

45. Q1978481

46. 1-tert-butoxycarbonylamino-cyclopent-3-enecarboxylicacid

47. 16-methylene-17.alpha.-acetoxy-19-nor-pregn-4-ene-3,20-dione

48. 17-(acetyoxy)-16- Methylene -19-nonpregn-4-ene-3,20-dione

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 370.5 g/mol
Molecular Formula C23H30O4
XLogP32.9
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass370.21440943 g/mol
Monoisotopic Mass370.21440943 g/mol
Topological Polar Surface Area60.4 Ų
Heavy Atom Count27
Formal Charge0
Complexity762
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Segesterone acetate in combination with ethinyl estradiol is indicated for use by females of reproductive potential to prevent pregnancy as a combination hormonal contraceptive (CHC). It induces contraception for thirteen 28-day cycles (1 year) following vaginal administration. The vaginal system must remain in place continuously for 3 weeks (21 days) followed by a 1-week (7-day) vaginal system-free interval. The use in females with a body mass index of >29 kg/m^2 has not been adequately evaluated.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Segesterone acetate suppresses ovulation. In a Phase I randomized, placebo-controlled, randomized crossover study involving healthy adult female subjects, there was no clinically significant QTc interval prolongation following a single intravenous bolus dose of segesterone acetate. Segesterone acetate shows no androgenic, anabolic, or estrogenic activity. It also did not show uterotropic activity in ovariectomized rats. In the endometrial transformation test to assess the progestational activity, dose-dependent increases in both uterine weight was observed following subcutaneous administration of segesterone acetate.


5.2 MeSH Pharmacological Classification

Contraceptive Agents, Female

Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading. (See all compounds classified as Contraceptive Agents, Female.)


Contraceptive Agents, Hormonal

Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)


5.3 Absorption, Distribution and Excretion

Absorption

Contraceptive vaginal rings provided sustained release of contraceptive levels of segesterone acetate over 90 days in a pharmacokinetic study of healthy women. Following vaginal administration for up to 13 cycles, segesterone acetate was absorbed into systemic administration and reached the peak plasma concentration in 2 hours in Cycle 1, Cycle 3, and Cycle 13. Concentrations declined after time to reach plasma concentration (Tmax) and became more constant after 96 hours post-dose.Over subsequent cycles of use, the peak serum concentrations of segesterone acetate decreased. In Cycle 1, 3 and 13, the peak plasma concentrations were 1147, 363, and 294 pg/mL.


Route of Elimination

In a pharmacokinetic study, approximately 81.4% and 7.62% of the subcutaneously-administered dose in rats was excreted via feces and urine, respectively.


Volume of Distribution

The volume of distribution of segesterone acetate is 19.6 L/kg.


Clearance

No pharmacokinetic data available.


5.4 Metabolism/Metabolites

Segesterone acetate undergoes rapid metabolism and inactivation in the liver. Based on the findings _in vitro_, the major oxidative metabolites in the serum include 5-dihydro- and 17-hydroxy-5-dihydro metabolites constitute about 50% of exposure relative to segesterone acetate. The metabolites are not pharmacologically active with EC50 to progesterone receptor 10-fold higher than that of the parent compound. It was shown that 3, 5-tetrahydrosegesterone acetate acts as an activator at the GABA-A receptors in the brain.


5.5 Biological Half-Life

The mean (SD) half life of segesterone acetate is 4.5 (3.4) hours.


5.6 Mechanism of Action

Segesterone acetate selectively binds to the progesterone receptor (PR), a transcription factor belonging to the nuclear receptor superfamily, where it acts as an agonist and transactivator. According to the findings from docking experiments, it adopts the same docking position within the PR ligand-binding domain (LBD) as progesterone but due to additional stabilizing contacts between 17-acetoxy and 16-methylene groups and PR LBD, segesterone acetate display higher potency than progesterone. As with other progestins, segesterone acetate prevents ovulation by blocking the midcycle surge in luteinizing hormone (LH) secretion, thereby inhibiting the development of ovarian follicles. When used in combination with segesterone acetate, ethinyl estradiol potentiates the antigonadotropic of the progestin and prevents irregular shedding of the endometrium. Segesterone acetate lacks androgenic activity, and displayed binding affinity to androgen receptors that was 500- to 600-fold less than that of testosterone. It does not display binding affinity toward estrogen receptors. When the relative binding affinities of segesterone acetate to human steroid receptors were investigated _in vitro_, it was demonstrated that segesterone acetate binds to the glucocorticoid receptor. However, segesterone acetate did not exert any glucocorticoid activity in the _in vivo_ assays showing no increase in liver glycogen and tyrosine transaminase TAT.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Segesterone Acetate Manufacturers

A Segesterone Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Segesterone Acetate, including repackagers and relabelers. The FDA regulates Segesterone Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Segesterone Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Segesterone Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Segesterone Acetate Suppliers

A Segesterone Acetate supplier is an individual or a company that provides Segesterone Acetate active pharmaceutical ingredient (API) or Segesterone Acetate finished formulations upon request. The Segesterone Acetate suppliers may include Segesterone Acetate API manufacturers, exporters, distributors and traders.

click here to find a list of Segesterone Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Segesterone Acetate USDMF

A Segesterone Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Segesterone Acetate active pharmaceutical ingredient (API) in detail. Different forms of Segesterone Acetate DMFs exist exist since differing nations have different regulations, such as Segesterone Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Segesterone Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Segesterone Acetate USDMF includes data on Segesterone Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Segesterone Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Segesterone Acetate suppliers with USDMF on PharmaCompass.

Segesterone Acetate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Segesterone Acetate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Segesterone Acetate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Segesterone Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Segesterone Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Segesterone Acetate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Segesterone Acetate suppliers with NDC on PharmaCompass.

Segesterone Acetate GMP

Segesterone Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Segesterone Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Segesterone Acetate GMP manufacturer or Segesterone Acetate GMP API supplier for your needs.

Segesterone Acetate CoA

A Segesterone Acetate CoA (Certificate of Analysis) is a formal document that attests to Segesterone Acetate's compliance with Segesterone Acetate specifications and serves as a tool for batch-level quality control.

Segesterone Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Segesterone Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Segesterone Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Segesterone Acetate EP), Segesterone Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Segesterone Acetate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty